NCT03220854: SBRT + PD-1/PDL-1 Inhibiting Therapy for Advanced Solid Tumors After Progression on PD-1/PDL-1 Tx

NCT03220854
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Active, not recruiting
Phase 2
Drug Category: Therapeutic Antibody, Immunotherapy, Radiation therapy

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Senior)
Location of Metastases: Brain
Additional Notes: 
Exclusions: 
https://ClinicalTrials.gov/show/NCT03220854

Comments are closed.

Up ↑